Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) presented data from its Phase 1 trial of soquelitinib for moderate-to-severe atopic dermatitis at the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE